



## Sanofi and the Iran Ministry of Health and Medical Education Sign a Memorandum of Cooperation

*- Several projects will be studied to further develop existing local manufacturing collaborations and work on programs to fight chronic and non-communicable diseases -*

**Paris and Teheran - January 28, 2016** - [Sanofi](#) and the [Iran Food and Drug Administration](#), affiliated to the Ministry of Health and Medical Education of the Islamic Republic of Iran, have signed a Memorandum of Cooperation (MoC) to start discussions in order to explore the possibilities in which Sanofi may lend its know-how and expertise to benefit the citizens of the Islamic Republic of Iran.

*"Sanofi has built a long term presence in Iran and, as the n°1 multinational healthcare company in this country, is committed to delivering both innovative and well established healthcare solutions to citizens of Iran,"* said Serge Weinberg, Chairman of the Board of Directors, Sanofi. *"With this cooperation, we will consider the possibility to increase our footprint in Iran, where we have been operating for more than 10 years, and reinforce our ongoing industrial collaborations."*

The Memorandum addresses three areas of discussion and potential collaboration:

Sanofi will study ways in which it could potentially further develop its current partnerships with reputable Iranian manufacturers to enhance the sharing of its expertise in industrial quality standards and to increase the transfer of its pharmaceutical production technology and know-how to manufacture high quality pharmaceutical products in several fields of chronic and non-communicable diseases to reputable and reliable Iranian manufacturers.

Sanofi will collaborate with the Ministry of Health on programs for the prevention and control of certain chronic and non-communicable diseases and on managing related risk factors, notably diabetes.

The third area will be on evaluating possible collaborations to improve the availability of accurate, reliable, and meaningful epidemiological studies and registries. Both Sanofi and Ministry of Health agree that these are critical to permit policy makers to create and shape effective and socially impactful policies in the health sector. Therefore, Sanofi will explore the possibilities and feasibility of engaging the Iranian scientific society to work in these areas, and obtain and make available to the Ministry of Health Sanofi's extensive knowledge in epidemiological studies and registries on both national and international scales to help policy makers to address the chronic and non-communicable diseases areas such as diabetes, cardiovascular diseases, multiple sclerosis and rare diseases.

All evaluations will be done in accordance with applicable laws, including trade restriction rules.

## About Sanofi in Iran

Sanofi established a legal presence in the Islamic Republic of Iran in 2006 through a representative office. Also, Sanofi has been developing its presence in the Islamic Republic of Iran since 2009 through establishing of manufacturing collaborations for some of its core pharmaceutical products with key local Iranian partners and thus engaged in significant technology and know-how transfer. As a result, 55 % of the sales in Iran are with locally manufactured products.

## About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare including diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

## Forward-Looking Statements

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

## Contacts:

### Media Relations

**Laurence Bollack**

Tel. : +33 (0)1 53 77 46 46

[mr@sanofi.com](mailto:mr@sanofi.com)

### Investor Relations

**Sébastien Martel**

Tel. : +33 (0)1 53 77 45 45

[ir@sanofi.com](mailto:ir@sanofi.com)